å¹´é ã«ãããå ç«æ©è½ã«ãã£ã¦æ²æ» ã§ããæ¥ãè¿ã¥ãã¦ããã®ã§ã¯ã¨å¤¢ãèªã£ãï¼ãããå¾å§ãã®å夢ãå®ç¨è¦æ®ãããå ç«çæ³CARTããéºä¼åã¨ã¯ã½ã¼ã 解æãã西å·ä¼¸ä¸ãåç §ï¼ã ãæ¨å¹´çºè¡¨ãããããã¡ã©æåå容ä½Tç´°èçæ³ï¼Chimera Antigen Receptor T therapyï¼CARTï¼ãã¨ããæè¡ã¨ãå ç«ãå¼±ããã·ã¹ãã ã«å¯¾ããæä½æ²»çãæPD-1ã æPDL-1ãæCTLA4ã¨ããæä½ã«ã¤ãã¦ã®è«æã®çµæã極ãã¦å°è±¡çã§ãæå¾ ãä¸ãã¦ãããããã ã ããã æ£ç´ã«è¨ãã¨ãæä½æ²»çã«ã¤ãã¦ã¯ã©ããã¦ãä»ã®æ¸å¿µãé ããããã ææ°éã®è¬ã¯ã³ã¹ããèª²é¡ çç±ã¯ãã³ã¹ããã ãå¤ãã®ããã«å¹ããã¨ãæããã«ãªã£ãå ´åãï¼åæ°åä¸åããæä½ãé·æéæã¡ç¶ãããã¨ãçµæ¸çã«å¯è½ããä»å¾è°è«ãç¶ãæ°ãããã ãCTLA-4ã¨PD-1ãæ¯ã¹ãã¨ããCTLA-4ã¯è¤éã§çµæ¸æ§ã®å£ãè¶ããã®ã¯å®¹æã§
{{#tags}}- {{label}}
{{/tags}}